Maxcyte (MXCT) Non-Current Deffered Revenue (2021 - 2022)
Maxcyte (MXCT) reported Non-Current Deffered Revenue of $344600.0 for Q3 2022, down 23.46% quarter-over-quarter from $450200.0 in Q4 2021.
Maxcyte (MXCT) Non-Current Deffered Revenue (2021 - 2022) Analysis & Trends
Maxcyte (MXCT) has 2 years of Non-Current Deffered Revenue data on file, last reported at $344600.0 in Q3 2022.
- Non-Current Deffered Revenue for Q3 2022 came in at $344600.0, changed N/A year-over-year; the trailing twelve-month figure through Sep 2022 was $344600.0 (changed N/A YoY), and the FY2021 annual result was $450200.0, changed N/A from the prior year.
- Non-Current Deffered Revenue slipped to $344600.0 in Q3 2022 per MXCT's latest filing, from $450200.0 in the prior quarter.
- Over five years, Non-Current Deffered Revenue peaked at $450200.0 in Q4 2021 and troughed at $344600.0 in Q3 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 154.42 Bn | 147.76 Bn | 6.27 Bn | - |
| 2 | Stryker | 118.12 Bn | 115.25 Bn | 3.81 Bn | - |
| 3 | Medtronic | 101.72 Bn | 93.55 Bn | 5.76 Bn | - |
| 4 | Boston Scientific | 67.19 Bn | 65.98 Bn | 3.61 Bn | - |
| 5 | Edwards Lifesciences | 50.69 Bn | 47.02 Bn | 1.29 Bn | - |
| 6 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn | 512.79 Mn |
| 7 | Dexcom | 28.09 Bn | 26.97 Bn | 750.30 Mn | - |
| 8 | GE HealthCare Technologies | 28.08 Bn | 26.02 Bn | 1.98 Bn | - |
| 9 | Steris | 19.80 Bn | 19.37 Bn | 697.10 Mn | - |
| 10 | Maxcyte | 127.72 Mn | 127.72 Mn | 8.08 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2022 | 344,600.00 |
| Dec 31, 2021 | 450,200.00 |